Our Team
Rooted in Science. Driven by Purpose.
At Hummsa, we believe that solving some of the world’s most complex health challenges starts with assembling the right minds. Our team blends visionary leadership with deep scientific expertise, united by a mission to reimagine chronic disease care for a healthier, longer-living world.
Leadership Team
Our leadership team combines scientific insight and strategic vision to drive Hummsa’s mission of transforming chronic disease care from the ground up.
Harshad Lalwani is the founder and CEO of Hummsa Biotech, developing novel therapeutics for metabolic disorders that shape human longevity.
Harshad Lalwani is the founder and CEO of Hummsa Biotech, developing novel therapeutics for metabolic disorders that shape human longevity.
He leads the company's mission to translate cutting-edge research into life-extending treatments through rigorous scientific validation and first-principles thinking.
Operating from emerging markets with global ambitions, Harshad combines strategic business acumen with deep scientific understanding. His leadership focuses on sustainable innovation, balancing commercial viability with meaningful impact in addressing age-related metabolic diseases.
His leadership combines experience from capital-intensive industries like real estate and defence with a deep focus on scientific rigor and strategic clarity. Under his direction, Hummsa is advancing a novel pipeline targeting chronic diseases that impact global longevity and quality of life.A lifelong athlete and student of both ancient strategy and modern systems, Harshad leads with intensity, discipline, and long-game focus.
His philosophy?
Build lean. Think deep. Deliver science that lasts.
Scientific Advisors
Our Scientific Advisory Board comprises internationally recognised experts in chronic metabolic diseases, drug development, and systems biology. Their insights guide our research, pipeline development, and clinical strategy.
Dr. Timo Müller pioneered gut hormone polyagonists and peptide-mediated nuclear hormone delivery, advancing obesity and diabetes therapies via GIPR/GLP-1 insights.
Timo Müller is an internationally renowned scientists who made significant strides in obesityand diabetes research, marked by a series of groundbreaking discoveries and development ofseveral innovative pharmacological concepts for the treatment of obesity and diabetes. Beingcontinuously at the forefront of diabetes research, Dr. Müllers contributions have significantlyadvanced our understanding of how gut hormone therapeutics can be used to treat obesityand diabetes. Dr. Müller is part of an international team of scientists who pioneered thedevelopment of unimolecular polyagonists at the receptors for GLP-1, GIP and Glucagon forthe treatment of obesity and diabetes. He further demonstrated that GLP-1-basedcombination-therapies offer enhanced glucometabolic efficacy in obese rodents (Clemmensen et al., Diabetes 2014, Clemmensen et al., EMBO Mol Med 2015) and co-pioneered the conceptof peptide-mediated nuclear hormone delivery as a new pharmacological strategy to treatobesity, diabetes and dyslipidemia (Finan et al., Cell 2016; Sachs et al., Nat Metab 2020;Quarta et al., Nat Metab 2022). This innovative pharmacological concept resides in that thenuclear hormone only enters and acts on cells that express the designated peptide hormonereceptor, thereby synergizing with the carrier peptide in the target cell to maximize metabolicefficacy while limiting off-target effects in cells devoid of the peptide receptor. Beyond thisinnovative novel concept, Müller identified several novel pathways implicated in body weightand glucose control (Müller et al., Nat Commun 2013; Müller et al., JCI 2013; Fischer et al.,Nat Commun 2020). He is further recognized worldwide for his work that identified the CNSGIP receptor as a key regulator underlying the decrease of body weight and food intake byGIPR agonism and GIPR:GLP-1R co-agonism (Zhang et al., Cell Metab 2021). In follow-upmanuscripts, he discovered the neuronal population by which GIPR agonism regulates bodyweight and feeding (Liskiweicz et al., Nat Metab 2023) and that GIPR agonism and antagonismdecrease body weight and food intake via different mechanisms (Gutgesell et al., Nat Metab2025). In light of the clinical success of the recently approved GIPR:GLP-1R co-agonistTirzepatide, Dr. Müller’s studies not only significantly contribute to our understanding of howthese novel drugs act in the brain to control energy and glucose metabolism, but also pave theway to selectively target the GIP system using next generation drugs.
Dr. Müller has a H-factor of 62 (based on google scholar) and a track record of 200+manuscripts, including manuscripts in Cell, Nature Medicine, Cell Metabolism, NatureMetabolism, JCI and Nature Communications. His recognitions include the Galenus-von-Pergamon Award of Springer Medicine, the Werner Creutzfeldt Award from the GermanDiabetes Association, and the Minkowski Award from the European Association for the Studyof Diabetes (EASD).
Professor of Medicine, Harvard Medical School; Senior Investigator & Co-Head, Section on Islet & Regenerative Biology, Joslin Diabetes Center
Dr. Rohit N. Kulkarni is an internationally recognised scientist in diabetes and metabolism research, with pioneering expertise in beta cell biology, GLP-1 therapeutics, and metabolic disease pathways.
The significance of his work lies in enhancing functional beta cell numbers and developing transformative approaches for treating diabetes and obesity—research directly aligned with Hummsa Biotech's therapeutic pipeline.
His distinguished scientific contributions have earned prestigious recognition, including the Endocrine Society's Ernst Oppenheimer Award and the EASD Albert Renold Prize. As an elected member of the American Society for Clinical Investigation, the Association of American Physicians, and the American Association for the Advancement of Science, he represents the highest calibre of scientific excellence.
Currently serving as Professor of Medicine at Harvard Medical School and Senior Investigator at the Joslin Diabetes Center, Dr. Kulkarni brings invaluable strategic insight from his extensive experience with global pharmaceutical companies, guiding Hummsa Biotech through complex drug development pathways and regulatory landscapes.
Contact us
Phone
